Our latest whitepaper from MabPlex explores how large scale ADC production can be made more robust through the latest technologies. Download the full whitepaper here.
Antibody drug Conjugates (ADCs) represent a potent therapeutic for targeted delivery of toxins to specific cell types. There are many ADC candidates currently in clinical development, with more than 10 entering Phase II and III clinical trials. However, large-scale production of ADCs has been hampered by a number of factors, including:
- The lack of efficient and consistent conjugation of antibody to the desired toxic compound
- Inconsistent antibody internalization
- Unstable linkers that release the toxin prior to arrival at the target tissue.
This whitepaper discusses the state of the art solutions to these problems to allow robust, large-scale production of ADCs with predictable and consistent conjugation efficiency using a variety of linkers.